跳转至内容
Merck
CN

Y0001580

罗库溴铵 溴化物

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C32H53BrN2O4
分子量:
609.68
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

rocuronium

制造商/商品名称

EDQM

溶解性

H2O: 100 mg/mL, clear, light yellow

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

−20°C

SMILES字符串

[Br-].CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCOCC5)[N+]6(CCCC6)CC=C

InChI

1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1

InChI key

OYTJKRAYGYRUJK-FMCCZJBLSA-M

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Rocuronium bromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

Aminosteroid; neuromuscular blocker for anaesthesia

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbones

警示用语:

Danger

危险声明

危险分类

Acute Tox. 3 Oral - STOT SE 3

靶器官

Respiratory system

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

S Agoston
European journal of anaesthesiology. Supplement, 9, 107-111 (1994-01-01)
A review of several publications shows that there is general agreement that inhalational anaesthetic agents potentiate the neuromuscular effects of rocuronium in the same order as other similar agents, namely; enflurane and isoflurane > halothane > intravenous anaesthetics. However, such
D Steinberg
Revista espanola de anestesiologia y reanimacion, 56(10), 604-611 (2010-02-16)
The correlation between gender and the potency of certain neuromuscular blockers, including rocuronium, has been investigated. However, the methods used have been inconsistent. This study aimed to look further at the role of gender in order to arrive at definitive
T Wang et al.
Anaesthesia, 69(8), 854-859 (2014-05-14)
We investigated whether laparoscopic vs open surgical approaches affected the duration of neuromuscular blockade following a single bolus dose of rocuronium. Fifty-three female patients underwent either laparoscopic or open gynaecological surgery. Rocuronium 0.6 mg.kg(-1) was administered to achieve neuromuscular blockade
J M Hunter
European journal of anaesthesiology. Supplement, 11, 39-41 (1995-09-01)
The pharmacokinetics of aminosteroid neuromuscular blocking drugs have been shown to be altered in patients with hepatic cirrhosis. A reduced clearance and prolonged elimination half-life of pancuronium and vecuronium have been demonstrated. Pharmacokinetic studies of the newest aminosteroid neuromuscular blocking
Hiroshi Iwasaki
Masui. The Japanese journal of anesthesiology, 55(7), 826-833 (2006-07-22)
For many years, much effort has been done to develop non-depolarizing neuromuscular blocking agents of rapid onset and short duration. It has been shown that rocuronium bromide is a nondepolarizing, steroidal muscle relaxant with fast onset and short-to-intermediate duration of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门